Scott Milligan, PhD
Articles
July 12th 2019
Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017
Naoky Tsai, MD Bruce Bacon, MD Michael Curry, MD Steven L. Flamm, MD Scott Milligan, PhD Nicole Wick, AS Zobair Younossi, MD Nezam Afdhal, MD
From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.
April 21st 2014
Physician Behavior Impact When Revenue Shifted From Drugs to Services
Bruce Feinberg, DO Scott Milligan, PhD Tim Olson, MBA Winston Wong, PharmD Daniel Winn, MD Ram Trehan, MD Jeffrey Scott, MD
Shifting physician revenue from drug sales to cognitive services for mature pathways providers did not affect practice behavior in this payer-sponsored Oncology Medical Home.
May 18th 2012
Bruce A. Feinberg, DO James Lang, PharmD, MBA James Grzegorczyk, MS, RPh Donna Stark, RPh, MBA Thomas Rybarczyk, RN, BSN Thomas Leyden, MBA Joseph Cooper Thomas Ruane, MD Scott Milligan, PhD Philip Stella, MD Jeffrey A. Scott, MD
A statewide collaboration between payers and providers to create a cancer clinical care pathways program is successful.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: December 12th 2024 | Updated: December 18th 2024
Improving Access to Nivolumab by Lowering Age Restrictions in Clinical Trial
